Viralytics Ltd (AX:VLA) will present updates on three Phase Ib trials of Cavatak in combination with marketed immune checkpoint inhibitor (ICI) drugs at the AACR conference in the first week of April, including two prestigious podium presentations. The presentations will include preliminary data from the MITCI and CAPRA intralesional injection trials and an update on the Keynote 200 (STORM) IV Cavatak trial. We leave our valuation unchanged at A$385m or A$1.60/share as we await the updates.
Preliminary data on Cavatak intralesional combos…
Viralytics will present updates on three Phase Ib trials that are testing its Cavatak oncolytic virus immunotherapy in combination with marketed ICI drugs at the American Association for Cancer Research (AACR) conference in Washington DC on 1-5 April. Updated preliminary results will be presented on two studies of Cavatak delivered by intratumoural injection in melanoma patients, in combination with IV doses of either Keytruda (in CAPRA) or Yervoy (in the MITCI study).
To read the entire report Please click on the pdf File Below